Dr. John Cush RheumNow
5 months 1 week ago
TRACE study in 90 active axSpA, biologic-naïve, Rx w/ secukinumab 150 mg; @wk16 ASDAS remission in 30 (35%)& 55 incr SEC to 300 mg. By wk 24, 22% of 300 mg achieved ASDAS remission; but without signif change in MRI inflamm (SPARCC). Most MRI changes in 1st 4wks https://t.co/pMMtrxxDLh
Dr. John Cush RheumNow
5 months 1 week ago
Still's Disease Update
Arthritis Research & Therapy has published an overarching review of Still's disease, claiming it is a single acquired, complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations, and https://t.co/8ctddvIq7k
Dr. John Cush RheumNow
5 months 1 week ago
Simulation cost-effectiveness/QOL study compared Rx of psoriasis w/ biologics, phototherapy, or step-therapy Rx. Biologics had best QOL gains; step-therapy Rx similar w/ less variability & lower costs; phototherapy was cost-effective for payors. Pts had highest willingness to pay https://t.co/RyNooKhgQh
Dr. John Cush RheumNow
5 months 1 week ago
Physician Use of Augmented Intelligence has Doubled
A 2026 Physician Survey assessing AI and its use in Medical Practice has been published and follows earlier surveys on adoption and use. This is the third in a series of longitudinal surveys (prior waves 2023, 2024), enabling https://t.co/4QoMR17Ure
Dr. John Cush RheumNow
5 months 1 week ago
Cross-sectional study from UK Clinical Practice Research Datalink Aurum looked at > 40K w/ #PMR Rx w/ steroids - 67% were coprescribed bisphosphonates (BP) & 79% Rx PPIs/H2RAs (less in males & pts deprived areas) resulting more Fx w/in 12 mos (2.32% vs 1.4%). https://t.co/b2DFJMjqCu
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Dr. John Cush RheumNow
5 months 1 week ago
Retrospective study of 374 newly diagnosed microscopic polyangiitis (MPA) pts - 97 (26%) had severe infections w/in 6 mos - signif higher risk w/ high dose prednisone & chronic lung Dz. most common: bacterial (43%) & lung infx https://t.co/XXAxUZw7kx https://t.co/atK8Ob9zyQ
Dr. John Cush RheumNow
5 months 1 week ago
Modest Benefits with AI Scribes on EHR Documentation
Documenting patient visits in the EHR is essential to care, but a major contributor to clinician burnout. AI-enabled ambient documentation (“AI scribes”) can auto-generate draft clinical notes for clinician review. They may https://t.co/6HaUwpFYLC
Dr. John Cush RheumNow
5 months 2 weeks ago
Retrospective clinicopathologic review of 170 AORTIC surgical pathology cases (2009-16) - showed 87% w/ atherosclerosis, 13% aortitis/periaortitis and 2.4% atherosclerosis w/ excessive inflammation. Lymphoplasmacytic inflammation was most common w/ aortitis/periaortitis. https://t.co/CuP30dqRQU
Dr. John Cush RheumNow
5 months 2 weeks ago
152 pts w/ immune thrombocytopenia (ITP) Rx in DBRPCT of Ianalumab (9mg or 3 mg/kg) or PBO q mo x 4 mos (all on Eltrombopag). Time to Rx failure signif longer w/ ianalumab. Stable 6 month response better w/ 9-mg group vs PBO (62% vs 39%; P=0.045) https://t.co/J04trYAwLu https://t.co/Alm8V2SAXn
Dr. John Cush RheumNow
5 months 2 weeks ago
Litifilimab in Cutaneous Lupus Erythematosus
Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting. https://t.co/3Wb6iFViOm
The American College of Rheumatology (ACR) today thanked lawmakers in the U.S. House of Representatives for introducing the bipartisan Provider Reimbursement Stability Act of 2025 (H.R. 8163), legislation designed to stabilize Medicare payments for physicians and protect patient access to care.
An NEJM study has shown that glucocorticoids provide no added benefit when added to standard primary treatment in Kawasaki disease patients.
Arthritis Research & Therapy has published an overarching review of Still's disease - claiming it to be a single acquired and complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations and clinical presentations, with minor differences between children and adults who are afflicted.
